Advertorial Promotion – By Palvinder Deol
There has been a clear shift in the way women are approaching weight loss. For years, the conversation was dominated by diets, exercise plans, calorie counting and willpower. Those things still matter, but in 2026, more women are also looking at medically supported weight loss.
This is not because lifestyle is no longer important. It is because many women are realising that obesity is not simply a motivation problem. It is a complex medical issue affected by hormones, appetite regulation, genetics, sleep, stress, age, medication, pregnancy history and environment.
The data shows why this shift is happening.
Obesity is now a mainstream health issue
The latest Health Survey for England data shows that around 30% of adults in England are living with obesity. Among women, the figure is slightly higher at around 31%. The same data suggests that around 62% of women are now living with overweight or obesity.
That matters because weight is not just about appearance. Excess weight is linked with a higher risk of type 2 diabetes, high blood pressure, heart disease, sleep apnoea, joint pain, some cancers, and fertility and pregnancy complications.
For many women, the reason for seeking help is not just wanting to look different. It is wanting to feel better, move more easily, reduce health risks and regain control after years of trying to lose weight alone.
Why traditional diets often fail
Most women who seek medical support have already tried dieting. Often many times.
The problem is that weight loss is not just a question of knowing what to eat. When calorie intake falls, the body responds. Hunger can increase, fullness can reduce, energy expenditure may drop and cravings may become harder to manage.
This is one reason why people often lose weight at first, then regain it later. Research has consistently shown that long-term weight loss maintenance is difficult, particularly when people are relying on willpower alone.
That does not mean lifestyle changes are pointless. They are essential. But for some women, especially those living with obesity or weight-related health conditions, lifestyle changes may work better when combined with structured clinical support.
The rise of GLP-1 treatments
One of the biggest drivers of this change has been the arrival of GLP-1 receptor agonist medicines, including treatments such as Wegovy and Mounjaro. These medicines work by mimicking gut hormones involved in appetite and fullness. They can help some people feel fuller for longer, reduce cravings and eat smaller portions more comfortably.
This is very different from older ideas of dieting, where the patient is simply expected to tolerate hunger.
The UK market has changed quickly. Reuters reported that around 2.4 million people in the UK used GLP-1 medicines last year, with only around 200,000 accessing them through the NHS. The majority were using private providers.
That tells us something important. Demand is not only coming from people who qualify for NHS treatment. It is also coming from people who are actively looking for regulated, private medical support because they do not want to wait, or because they do not meet the strictest NHS criteria.
Women appear to be driving much of the demand
The gender pattern is also important. UK reporting on private weight loss prescribing has suggested that women make up the majority of people accessing these medicines privately, with particularly high use among women in their 30s and 40s.
That does not mean men are not affected by obesity. They are. But women are often more likely to seek help earlier, especially when weight is affecting confidence, fertility planning, menopause symptoms, mobility, energy or long-term health worries.
In pharmacy practice, this is something we see regularly. Women often come forward after years of trying different diets, not because they want a quick fix, but because they feel stuck.
They may be eating better than before. They may be exercising. They may still feel constantly hungry. That is where properly prescribed weight loss treatments can sometimes form part of a wider plan.
The NHS rollout is important, but access is still limited
In 2025, NHS England began a wider rollout of Mounjaro for people with the greatest clinical need. Around 220,000 patients are expected to receive treatment over the first three years of the programme.
That is significant, but it is still a small proportion of the people who may benefit from obesity treatment. The initial criteria are strict, focusing on people with a very high BMI and several weight-related conditions.
This is one reason private online pharmacy services have grown. For some women, private treatment offers faster access, more choice and the ability to start support before weight-related health issues become more serious.
But it must still be safe. That means proper eligibility checks, clinical screening, ongoing monitoring and advice about nutrition, side effects and realistic expectations.
Wegovy weight loss pills could change things again
The next major shift is the arrival of Wegovy weight loss pills. Until now, Wegovy has mainly been associated with weekly injections. That has worked well for many people, but injections are a barrier for others.
Needle anxiety is real. Some people delay treatment because they are uncomfortable injecting themselves, worried about doing it incorrectly, or simply do not like the idea of using a needle every week.
The UK approval of oral Wegovy tablets in June 2026 is therefore important. The tablets contain semaglutide, the same active ingredient used in Wegovy injections, but in a daily oral form. Clinical trial data reported around 14% to 17% weight loss over 64 weeks at the highest dose.
That is not a small result. For a woman starting at 90kg, a 15% reduction would be around 13.5kg.
For some patients, the convenience of a tablet may make treatment feel more acceptable. It may also appeal to women who travel often, have busy routines, or simply prefer not to use an injectable medicine.
But tablets are not automatically easier for everyone. Oral semaglutide needs to be taken carefully, usually on an empty stomach, with water, and with a waiting period before eating or drinking. That means the best option will still depend on the individual.
What this means in real life
The biggest misconception is that medical weight loss removes the need for lifestyle change. It does not.
The most successful outcomes usually happen when treatment is combined with higher protein meals, strength training or regular movement, smaller portions, better sleep, reduced alcohol intake, consistent follow-up and realistic targets.
The medicine can help reduce appetite, but it cannot build habits for you. It cannot choose balanced meals. It cannot maintain muscle. It cannot replace long-term behavioural change.
This is why pharmacy support matters. Patients need to understand how the treatment works, what side effects to expect, when to seek help and what happens if treatment is stopped.
Final thought
The rise in medical weight loss among women is not just a trend. It reflects a bigger change in how obesity is being understood.
More women are recognising that weight management is not always solved by another diet. The data shows obesity is common. The demand for treatment is growing. And new options, including Wegovy tablets, are likely to make medical weight loss feel more accessible for women who may previously have avoided injectable weight loss treatments.
But the message should stay balanced. Medical treatment can be a powerful tool. It is not a shortcut.
Used safely, with professional support and realistic expectations, it can help women move from repeated dieting to structured, evidence-based weight management.
Palvinder Deol is Superintendent Pharmacist at Happy Pharmacy, supporting patients with evidence-based weight management advice and regulated treatment options.
